News Review – Inovio Pharmaceuticals Inc (NASDAQ:INO), Nike Inc (NYSE:NKE)
Trading the news is a technique to trade equities, currencies and other financial instruments on the financial markets. Trading news releases can be a noteworthy tool for financial shareholders. Economic news reports often drive strong short-term moves in the markets, which may create trading opportunities for traders. Declarations about corporate profits, a change in administration, rumors of a merger, are events that can cause a company’s share price to move wildly up or down. Interest rates, unemployment and export rates, or the central bank’s policy shifts, can cause a deep change of an exchange rate.
Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) declined -10.62% to $6.06 on Thursday. The stock is currently trading at $6.06 per share, floating in a range of $6.00 to $6.28. The stock is moving on high volume, traded at a volume of 11.75 million shares, as compared to its average daily volume of 1.30 million shares. The market capitalization billion for the company is reported at $407.37 Million.
Nike Inc (NYSE:NKE) opened at $59.12. It reached an intraday trading high of $59.59 and now trading at $59.02. The stock price inclined 1.25 points or 2.16% at the market, after the athletic apparel and accessories giant headquartered in Beaverton, Oregon was upgraded at Morgan Stanley, which said headwinds and competitive pressures were waning.
Analyst Jay Sole raised his rating to overweight from equal weight and his stock price target to $68, which is 18% above Wednesday’s closing price of $57.77, from $54.
The total volume traded for the day is 6.65 million, as compared to its average daily volume of 10.88 million shares. The current EPS for the company has been recorded at $2.51 and the beta value recorded by the company stands at 0.60 points.
Sole said he has “raised conviction” in the company’s ability to grow North America sales to 5%, from the current decline of 2%, by mid-fiscal 2018. He said Nike’s supply chain benefits should accelerate over the medium term and that its operating model has competitive moats. “The opportunity to buy [Nike’s stock] at the bottom of a cycle is closing,” Sole wrote in a note to clients, with peers unable to emulate Nike’s operating model. (Source: MarketWatch)